X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
Nodar, Inc. specializes in manufacturing advanced sensors for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. The company offers innovative LiDAR technology and a 3D stereo vision system called Nodar Longbow, which is designed to enhance the capabilities of autonomous vehicles. Founded in 2018 and based in Boston, Massachusetts, Nodar aims to provide a cost-effective and high-performance solution for the automotive, marine, and railway industries. Their products, including the Hammerhead system, utilize off-the-shelf cameras to deliver precise depth sensing, targeting applications for level 3 and level 4 autonomous vehicles. This technology supports functions such as collision warning, path planning, and automatic emergency braking, contributing to improved safety and performance in the automotive sector.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
HOS is an AI technology company that develops scalable technologies to achieve significant and constructive changes in the world.
Neo Cybernetica specializes in the development of cybernetics technology aimed at enhancing the capabilities of artificial intelligence systems. By leveraging advanced communication and automatic control systems, the company focuses on creating AI systems that can operate independently as well as collaborate effectively with humans. This innovative approach positions Neo Cybernetica to address future opportunities and challenges, ultimately contributing to the advancement of AI technologies that can benefit society in the coming decades.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Candy is a multifaceted company that operates in the digital collectible and confectionery sectors. It develops sports and culture digital assets, providing authentic digital experiences that engage fans and connect them with their interests. Additionally, Candy.com serves as an online retailer catering to the growing demand for bulk, gourmet, and gift confectionery products, offering competitive pricing, expedited shipping, and a unique shopping experience. Furthermore, Candy Digital specializes in non-fungible tokens (NFTs), enabling fans to buy and trade officially licensed tokens related to Major League Baseball. Launched in 2021, this segment of the business was established by notable figures in the industry and reflects Candy's commitment to integrating technology with fan engagement.
Tulip Interfaces, Inc. is a company that specializes in developing applications for the manufacturing sector. Founded in 2012 and based in Somerville, Massachusetts, Tulip offers a Manufacturing App Platform that integrates data from various sources, including sensors, to create real-time digital work instructions and visualizations. This platform connects existing shop floor equipment with operator inputs, enhancing operational efficiency. Tulip's technology leverages advancements in intelligent hardware, computer vision, user interfaces, and machine learning, bridging the gap between traditional manufacturing IT systems and the dynamic needs of the shop floor. The company serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, with its solutions deployed across multiple global customers.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
New Wave Foods, Inc. specializes in producing and selling plant-based seafood products, focusing primarily on sustainable shrimp alternatives. Founded in 2015 and headquartered in San Francisco, California, the company offers a variety of items, including sautéed, grilled, breaded, and fried shrimp, as well as shrimp tacos and salads. Its products are made from sustainably sourced seaweed and soy protein, enriched with natural flavors and essential amino acids, providing a healthy, low-calorie, and zero-cholesterol option for consumers. Targeting the culinary market in the United States, New Wave Foods aims to preserve and enrich seafood traditions through its innovative plant-based offerings.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.
Berkshire Grey, Inc. specializes in developing artificial intelligence-driven robotic and automated material handling systems aimed at enhancing omnichannel fulfillment. Founded in 2013 and based in Lexington, Massachusetts, the company offers a range of solutions, including AI software, robotic arms, mobile robotic systems, and advanced sorting technologies. Its systems leverage artificial intelligence, computer vision, and machine learning to automate tasks traditionally performed by humans, thereby increasing accuracy and throughput in logistics and supply chain operations. Berkshire Grey's technology is designed to handle diverse products and packaging types, providing a significant competitive advantage to its customers. The company primarily generates its revenue from North America and operates as a subsidiary of SoftBank Group Corp.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Neural Magic is unlocking the possibility of machine learning, by re-imagining how deep learning is done. A team of pioneers, we believe machine learning has the potential to alter the trajectory of human history. Break free of limitations. Be a part of the future.
Neural Magic is unlocking the possibility of machine learning, by re-imagining how deep learning is done. A team of pioneers, we believe machine learning has the potential to alter the trajectory of human history. Break free of limitations. Be a part of the future.
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.
Tulip Interfaces, Inc. is a company that specializes in developing applications for the manufacturing sector. Founded in 2012 and based in Somerville, Massachusetts, Tulip offers a Manufacturing App Platform that integrates data from various sources, including sensors, to create real-time digital work instructions and visualizations. This platform connects existing shop floor equipment with operator inputs, enhancing operational efficiency. Tulip's technology leverages advancements in intelligent hardware, computer vision, user interfaces, and machine learning, bridging the gap between traditional manufacturing IT systems and the dynamic needs of the shop floor. The company serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, with its solutions deployed across multiple global customers.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
CATALOG is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation.
The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013 and based in Boston, Massachusetts, the company’s product pipeline includes CNTX-4975, currently undergoing Phase III trials for knee osteoarthritis pain and Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials for various chronic pain conditions, while CNTX-6970 targets inflammatory pain and CNTX-2022, a high-concentration topical gel formulation of lidocaine, is also in Phase I trials for superficial musculoskeletal pain and related conditions. Furthermore, CNTX-6016 is a pre-clinical candidate aimed at treating chronic neuropathic pain. Centrexion Therapeutics is committed to addressing the unmet medical needs in chronic pain treatment by focusing on safety and efficacy.
We offer a fully collaborative, modern digital experience for learning and communication. The Retrieve platform can be used by both education and enterprise clients. Teach and maintain courses, conduct student assessments. Communicate live or asynchronously via web conferences, discussion boards, and chat to students or remote employees. Share notes, files or images, distribute technical manuals, user guides and other documentation.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.
CATALOG is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation.
The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Tulip Interfaces, Inc. is a company that specializes in developing applications for the manufacturing sector. Founded in 2012 and based in Somerville, Massachusetts, Tulip offers a Manufacturing App Platform that integrates data from various sources, including sensors, to create real-time digital work instructions and visualizations. This platform connects existing shop floor equipment with operator inputs, enhancing operational efficiency. Tulip's technology leverages advancements in intelligent hardware, computer vision, user interfaces, and machine learning, bridging the gap between traditional manufacturing IT systems and the dynamic needs of the shop floor. The company serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, with its solutions deployed across multiple global customers.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Fam's mission is to build products that revolutionize the way teens and millennials communicate. They believe in a calculated combination of live group video and group chat messaging to execute this. It is the world’s first group video chat app for iMessage, with over 7 million users. Their app instantly connects with the family and friends closest to its user through group video calling, right from their iPhone, and Android text message app.
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.
Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.
Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.
ClearMotion, Inc., an automotive technology company, develops a suspension system that makes automotive systems that use a combination of hardware and software to anticipate, absorb, and counteract shocks and vibrations that cars pick up from the road. It specializes in suspension technology, road surface mapping, and active seating motion control aspects. ClearMotion, Inc. was formerly known as Levant Power Corporation and changed its name to ClearMotion, Inc. in January 2017. The company was incorporated in 2008 and is based in Billerica, Massachusetts with an operation in Nuneaton, United Kingdom.
ClearMotion, Inc., an automotive technology company, develops a suspension system that makes automotive systems that use a combination of hardware and software to anticipate, absorb, and counteract shocks and vibrations that cars pick up from the road. It specializes in suspension technology, road surface mapping, and active seating motion control aspects. ClearMotion, Inc. was formerly known as Levant Power Corporation and changed its name to ClearMotion, Inc. in January 2017. The company was incorporated in 2008 and is based in Billerica, Massachusetts with an operation in Nuneaton, United Kingdom.
Barkly is the endpoint protection platform that delivers the strongest protection with the fewest false positives and simplest management. Barkly's patented approach to protection combines Responsive Machine Learning with runtime behavior analysis to block file-based, fileless, and exploit attacks.
Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.
Onshape Inc., founded in 2012 and based in Cambridge, Massachusetts, is a developer of cloud-based 3D design software. The platform integrates computer-aided design (CAD) with data management, collaboration tools, and real-time analytics, enabling professional engineers to streamline their product development processes. Onshape's modern CAD system enhances productivity by providing secure, simultaneous access to a single master version of design data, which can be accessed from any device without data loss. The platform has been widely adopted by thousands of companies, facilitating the design of various products, including robotics and biomedical devices. In November 2019, Onshape was acquired by PTC Inc., further expanding its capabilities and market reach.
TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.
Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.
Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
DOTS (Detection On The Spot) is changing the field of point of care detection with a revolutionary diagnostics platform with consumer and industrial applications. For the millions of consumers with food allergies, DOTS is creating a food allergen detection system to test food on the spot, provide more information for better decisions, and improve overall quality of life .
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.
Acquia Inc. is a provider of a cloud-based platform designed to create, deliver, and optimize digital experiences for various industries, including government, education, and finance. Founded in 2007 and based in Boston, Massachusetts, Acquia offers a range of solutions such as Acquia Cloud, which supports the development and maintenance of Drupal websites, and Acquia Cloud Site Factory, which allows for the deployment of multiple sites. Their offerings also include Acquia Lift for creating tailored brand sites, Acquia Content Hub for content distribution, and Acquia Journey for data-driven customer engagement. Additionally, Acquia provides tools like Developer Studio for enhancing developer productivity and Acquia Digital Asset Manager for centralizing creative assets. The company's services aim to empower organizations to achieve impactful, contextually relevant digital experiences that enhance customer engagement.
Private Equity Round in 2015
Onshape Inc., founded in 2012 and based in Cambridge, Massachusetts, is a developer of cloud-based 3D design software. The platform integrates computer-aided design (CAD) with data management, collaboration tools, and real-time analytics, enabling professional engineers to streamline their product development processes. Onshape's modern CAD system enhances productivity by providing secure, simultaneous access to a single master version of design data, which can be accessed from any device without data loss. The platform has been widely adopted by thousands of companies, facilitating the design of various products, including robotics and biomedical devices. In November 2019, Onshape was acquired by PTC Inc., further expanding its capabilities and market reach.
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs.
It was founded in 2008 and headquartered in Cambridge, Massachusetts.
Barkly is the endpoint protection platform that delivers the strongest protection with the fewest false positives and simplest management. Barkly's patented approach to protection combines Responsive Machine Learning with runtime behavior analysis to block file-based, fileless, and exploit attacks.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.
CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.
CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.
Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.
Interleukin Genetics, Inc. is a genetics-focused personalized health company that develops genetic tests for sale to the emerging personalized health market. Their vision is to build a leading personalized health and wellness company. They believe that the science of applied genetics can empower individuals to personalize their health and provide valuable information to assist in drug development. They currently have two primary focus areas to their business. The first is personalized health, which is primarily focused on providing genetic test products to customers. These products are distributed via sales partners and their own sales channels, with the goal of providing guidance for the individual interested in improving their health and wellness. The second is a research and development effort focused on developing genetic tests linked to a partner’s products for marketing and sales into medical and dental channels. Both areas contribute toward their overall mission of providing products that can help individuals improve and maintain their health through preventive measures.
ClearMotion, Inc., an automotive technology company, develops a suspension system that makes automotive systems that use a combination of hardware and software to anticipate, absorb, and counteract shocks and vibrations that cars pick up from the road. It specializes in suspension technology, road surface mapping, and active seating motion control aspects. ClearMotion, Inc. was formerly known as Levant Power Corporation and changed its name to ClearMotion, Inc. in January 2017. The company was incorporated in 2008 and is based in Billerica, Massachusetts with an operation in Nuneaton, United Kingdom.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Solace Therapeutics, Inc. develops non-surgical office based treatments for unexpected bladder leaks in women. The company provides Vesair Bladder Control System, a non-surgical device that floats within the urinary bladder to eliminate and reduce involuntary urinary leakage. Its Vesair Bladder Control System is a non-surgical alternative to involuntary urinary leakage and a lightweight device to address the cause of stress urinary incontinence. The company was incorporated in 2002 and is based in Framingham, Massachusetts.
Acquia Inc. is a provider of a cloud-based platform designed to create, deliver, and optimize digital experiences for various industries, including government, education, and finance. Founded in 2007 and based in Boston, Massachusetts, Acquia offers a range of solutions such as Acquia Cloud, which supports the development and maintenance of Drupal websites, and Acquia Cloud Site Factory, which allows for the deployment of multiple sites. Their offerings also include Acquia Lift for creating tailored brand sites, Acquia Content Hub for content distribution, and Acquia Journey for data-driven customer engagement. Additionally, Acquia provides tools like Developer Studio for enhancing developer productivity and Acquia Digital Asset Manager for centralizing creative assets. The company's services aim to empower organizations to achieve impactful, contextually relevant digital experiences that enhance customer engagement.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Kensho Technologies, Inc. provides analytics, artificial intelligence, machine learning, and data visualization systems to global banks and investment institutions. It develops Kensho Financial Analytics Software that deploys scalable analytics systems across the commercial institutions. It also offers artificial intelligence (AI) software called Kensho Applied Mind. The company also operates a national security division called Koto. The company was incorporated in 2012 and is based in Cambridge, Massachusetts. It has additional offices in New York, New York; McLean, Virginia; and Pacific Palisades, California. As of April 8, 2018, Kensho Technologies, Inc. operates as a subsidiary of S&P Global Inc.
Onshape Inc., founded in 2012 and based in Cambridge, Massachusetts, is a developer of cloud-based 3D design software. The platform integrates computer-aided design (CAD) with data management, collaboration tools, and real-time analytics, enabling professional engineers to streamline their product development processes. Onshape's modern CAD system enhances productivity by providing secure, simultaneous access to a single master version of design data, which can be accessed from any device without data loss. The platform has been widely adopted by thousands of companies, facilitating the design of various products, including robotics and biomedical devices. In November 2019, Onshape was acquired by PTC Inc., further expanding its capabilities and market reach.
Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.
Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.
Onshape Inc., founded in 2012 and based in Cambridge, Massachusetts, is a developer of cloud-based 3D design software. The platform integrates computer-aided design (CAD) with data management, collaboration tools, and real-time analytics, enabling professional engineers to streamline their product development processes. Onshape's modern CAD system enhances productivity by providing secure, simultaneous access to a single master version of design data, which can be accessed from any device without data loss. The platform has been widely adopted by thousands of companies, facilitating the design of various products, including robotics and biomedical devices. In November 2019, Onshape was acquired by PTC Inc., further expanding its capabilities and market reach.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
It started with a simple observation: physicians need easier access to patient information. Since then, PatientKeeper has grown to become the leading physician information system provider. And for good reason. Since 1998, they've helped healthcare organizations cost-effectively deliver information where it's needed most to enhance patient care and safety, reduce costs, improve staff productivity and increase revenue. They offer the industry's only suite of applications that support physicians throughout their entire day — enabling them to review electronic patient records...write prescriptions...enter charges...dictate notes...document encounters...place orders...even consult with other caregivers — wherever they are. Their software addresses physician needs across virtually any device — ranging from handhelds to Smartphones to tablets, to laptops to desktop computers, so that whether they're reviewing test results in their office, in the car or at the bedside, they're covered. PatientKeeper customers can start with just a single application and add new capabilities as needed — with PatientKeeper all their applications are tightly integrated with each other. And because their platform integrates with existing healthcare systems, there's no need to replace legacy systems.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Solace Therapeutics, Inc. develops non-surgical office based treatments for unexpected bladder leaks in women. The company provides Vesair Bladder Control System, a non-surgical device that floats within the urinary bladder to eliminate and reduce involuntary urinary leakage. Its Vesair Bladder Control System is a non-surgical alternative to involuntary urinary leakage and a lightweight device to address the cause of stress urinary incontinence. The company was incorporated in 2002 and is based in Framingham, Massachusetts.
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.
Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.
It started with a simple observation: physicians need easier access to patient information. Since then, PatientKeeper has grown to become the leading physician information system provider. And for good reason. Since 1998, they've helped healthcare organizations cost-effectively deliver information where it's needed most to enhance patient care and safety, reduce costs, improve staff productivity and increase revenue. They offer the industry's only suite of applications that support physicians throughout their entire day — enabling them to review electronic patient records...write prescriptions...enter charges...dictate notes...document encounters...place orders...even consult with other caregivers — wherever they are. Their software addresses physician needs across virtually any device — ranging from handhelds to Smartphones to tablets, to laptops to desktop computers, so that whether they're reviewing test results in their office, in the car or at the bedside, they're covered. PatientKeeper customers can start with just a single application and add new capabilities as needed — with PatientKeeper all their applications are tightly integrated with each other. And because their platform integrates with existing healthcare systems, there's no need to replace legacy systems.
TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient.
Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.